Nicholas J. Vogelzang, MD
Combining lenvatinib (Lenvima) and pembrolizumab (Keytruda) led to a 25% overall response rate (ORR) in patients with urothelial carcinoma and was also associated with a manageable safety profile, according to results of a phase Ib/II trial that were presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Vogelzang suggested that these results warrant further investigation of the combination regimen for patients with urothelial cancer. The lenvatinib plus pembrolizumab combination will be explored further in a phase III trial for patients with urothelial cancer, and is also being studied in endometrial cancer and renal cell cancer.
Vogelzang NJ, Encarnacion CA, Cohn AL, et al. Phase 1b/2 trial of lenvatinib plus pembrolizumab in urothelial cancer. J Clin Oncol. 2019;37(suppl 8; abstr 11).
... to read the full story